



PubMed

Nucleotide

Protein

Genome

Structure

PMC

Taxonomy

OMIM

Bc

Search PubMed



for



Limits

Preview/Index

History

Clipboard

Details

About Entrez

Display

Abstract



Show:

20



Sort



Send to

Text



Text Version

☐ 1: Wiad Lek 1990 Jan 1-15;43(1-2):4-9[Related Articles, Link](#)

Entrez PubMed

[Overview](#)[Help | FAQ](#)[Tutorial](#)[New/Noteworthy](#)[E-Utilities](#)

PubMed Services

[Journals Database](#)[MeSH Browser](#)[Single Citation Matcher](#)[Batch Citation Matcher](#)[Clinical Queries](#)[LinkOut](#)[Cubby](#)

Related Resources

[Order Documents](#)[NLM Gateway](#)[TOXNET](#)[Consumer Health](#)[Clinical Alerts](#)[ClinicalTrials.gov](#)[PubMed Central](#)[Privacy Policy](#)

[Angiogenic activity of mononuclear cells in the peripheral blood of patients with ischemic heart disease]

[Article in Polish]

Pawinska M, Laniewska I, Sztorc M, Syska J, Wroblewski T, Kuch J.

Katedry i Kliniki Kardiologii II Wydziału Lekarskiego Ak. Med.,
Warszawie.

In the paper the cell-mediated phase of the immune response was assessed in ischaemic heart disease (IHD). The assessment was based on the angiogenesis test in which new capillaries are formed from the already existing vascularization. The process is mediated by mononuclear cells from peripheral blood, and is induced by degradation products appearing as a result of ischaemic injury to the tissues. The test was carried out in 71 patients with IHD and in 65 clinically healthy subjects. A significant fall was demonstrated of the angiogenic activity of mononuclear cells isolated from the peripheral blood of IHD patients as compared with controls (p less than 0.001). No effect was method of disease duration, its form or treatment on angiogenesis. The obtained results may suggest a failure of the immune system competent in this process in IHD. Perhaps this is related to a special form of IHD.

PMID: 1695042 [PubMed - indexed for MEDLINE]

Display

Abstract



Show:

20



Sort



Send to

Text

[Write to the Help Desk](#)[NCBI | NLM | NIH](#)[Department of Health & Human Services](#)[Freedom of Information Act | Disclaimer](#)

Mar 17 2003 10:44:0

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspcal642cxy

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BELSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDS
NEWS 6 Apr 22 Records from IP.com available in CAPUS, HCAPUS, and ZCAPUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 Jun 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FORGE no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
NEWS 14 Jul 29 saved answer sets no longer valid
NEWS 15 Jul 30 Enhanced polymer searching in REGISTRY
NEWS 16 Aug 08 NEFFIRST to be removed from STN
NEWS 17 Aug 08 PHARMALIT reload
NEWS 18 Aug 08 PHARMALIT reload (PHARMAL) - new on STN
NEWS 19 Aug 19 NTIS has been reloaded and enhanced
NEWS 20 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
NEWS 21 Aug 19 now available on STN
NEWS 22 Aug 19 IFIPAT, IFICDB, and IFIUDS have been reloaded
NEWS 23 Aug 26 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 24 Sep 03 Sequence searching in REGISTRY enhanced
NEWS 25 Sep 16 JAP10 has been reloaded and enhanced
NEWS 26 Sep 16 Experimental properties added to the REGISTRY file
NEWS 27 Oct 01 CA Section Thesaurus available in CAPUS and CA
NEWS 28 Oct 21 CASREACT Enriched with Reactions from 1907 to 1985
NEWS 29 Oct 24 EVENTLINE has been reloaded
NEWS 30 Oct 24 BELSTEIN adds new search fields
NEWS 31 Oct 24 Nutracuticals International (NUTRACUT) now available on STN
NEWS 32 Nov 18 MEDLINE SDI run of October 8, 2002
NEWS 33 Nov 25 DKILIT has been renamed APOLLIT
NEWS 34 Dec 02 More calculated properties added to REGISTRY
NEWS 35 Dec 04 TIBKAT will be removed from STN
NEWS 36 Dec 17 CSA files on STN
NEWS 37 Dec 17 PCTFULL now covers WP/BCT Applications from 1978 to date
NEWS 38 Dec 17 TOXCENTER enhanced with additional content
NEWS 39 Dec 17 Adis Clinical Trials insight now available on STN
NEWS 40 Jan 21 ISMCC no longer available
NEWS 41 Jan 21 NUTRACUT offering one free connect hour in February 2003
NEWS 42 Jan 21 PHARMALIT offering one free connect hour in February 2003
NEWS 43 Jan 21 Simultaneous left and right truncation added to COMPENDEX,
NEWS 44 Feb 13 ENERGY, INSPEC
NEWS 45 Feb 13 CANCERLIT is no longer being updated
NEWS 46 Feb 24 METADEX enhancements
NEWS 47 Feb 24 PCTGEN now available on STN
NEWS 48 Feb 24 TEMA now available on STN
NEWS 49 Feb 26 NTIS now allows simultaneous left and right truncation

NEWS 47 Feb 26 PCTFULL now contains images
NEWS 48 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 49 Mar 19 APOLLIT offering free connect time in April 2003
NEWS 50 Mar 20 APOLLIT will be removed from STN
NEWS 51 Mar 20 EVENTLINE now available on STN
NEWS 52 Mar 24 PANDPAPUL now available on STN
NEWS 53 Mar 24 Additional information for trade-named substances without
NEWS 54 Mar 24 structures available in REGISTRY
NEWS 55 Mar 24 Indexing from 1957 to 1966 added to records in CA/CAPUS
NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,
CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (General Information)

Enter NEWS followed by the item number or name to see news on that specific topic.
All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 14:58:10 ON 31 MAR 2003
=> file medicine, cancerlit, biosis, confaci, scisearch, embase, capus, uspatfull,
pctfull
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL
FULL ESTIMATED COST 0.21 0.21
FILE 'MEDLINE' ENTERED AT 14:58:42 ON 31 MAR 2003
FILE 'CANCERLIT' ENTERED AT 14:58:42 ON 31 MAR 2003
FILE 'BIOSIS' ENTERED AT 14:58:42 ON 31 MAR 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)
FILE 'CONFSCI' ENTERED AT 14:58:42 ON 31 MAR 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)
FILE 'SCISEARCH' ENTERED AT 14:58:42 ON 31 MAR 2003
COPYRIGHT (C) 2003 Institute for Scientific Information (ISI) (R)
FILE 'EMBASE' ENTERED AT 14:58:42 ON 31 MAR 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.
FILE 'CAPUS' ENTERED AT 14:58:42 ON 31 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE 'HELP USAGETERMS' FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'USPATFULL' ENTERED AT 14:58:42 ON 31 MAR 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'PCTFULL' ENTERED AT 14:58:42 ON 31 MAR 2003

COPYRIGHT (C) 2003 Univentio

=> s bone (a) marrow
L1 617302 BONE (A) MARROW

=> s 11 and mononuclear (a) cell
2 FILES SEARCHED...
L2 23479 L1 AND MONONUCLEAR (A) CELL

=> s 12 and angiogenesis?
L3 1465 L2 AND ANGIOGENESIS?

<-----User Break----->

SEARCH ENDED BY USER

=> s 12 and vessel?
L4 2771 L2 AND VESSEL?

=> dup rem 13
PROCESSING IS APPROXIMATELY 47% COMPLETE FOR L3
PROCESSING IS APPROXIMATELY 80% COMPLETE FOR L3
L5 1393 DUP REM L3 (72 DUPLICATES REMOVED)

=> s 15 not PY=>2000
*2000: NOT A VALID FIELD CODE
5 FILES SEARCHED...
L6 211 L5 NOT PY=>2000

=> d 1-20

L6 ANSWER 1 OF 211 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
DN 2000:24767 BIOSIS
PREV200000024767
TI Local transplantation of autologous bone marrow
-derived mononuclear cells augments collateral vessel
formation in ischemic hindlimb in rabbits.
AU Shintani, Satoshi (1); Murohara, Toyooki; Ueno, Takafumi; Ikeda, Hisao;
Duan, Junli; Imazumi, Tetsuomu
CS Circulation. (Nov. 2, 1999) Vol. 110, No. 18 SUPPL., PP. I-406.
Meeting Info.: 72nd Scientific Sessions of the American Heart Association
Atlanta, Georgia, USA November 7-10, 1999
ISSN: 0009-7322.

DT Conference
LA English

L6 ANSWER 2 OF 211 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
AN 1986:198123 BIOSIS
BA81:89423
TI ANGIOGENESIS IN ORGANIZING THROMBI NEW FINDINGS.
AU PERG W, LEU H J, LINTNER F, PEDIO G, SUSANI M
CS INSTITUT. ALLG. POLIKLINIK DER STADT WIEN, MARIANNENGASSE 10, A-1090 WIEN.
SO VASA. (1985 (RECD 1986)) 14 (4), 371-378.
CODEN: VASAAH.

FS BA: OLD
LA German

L6 ANSWER 3 OF 211 SCISEARCH COPYRIGHT 2003 ISI (R)
AN 2000:11869 SCISEARCH
CA The Genuine Article (R) Number: 2810J
TI Identification of IFN-gamma-producing cells in IL-12/IL-18-treated mice
AU Orenti T (Reprint); Nakamura S; Toki M; Moroda R; Kurimoto M; Orita K

CS HAYASHIBARA BIOCHEM LABS INC, FUJISAKI CELL CTR, OKAYAMA, JAPAN (Reprint);
HAYASHIBARA BIOCHEM LABS INC, FUJISAKI INST, OKAYAMA, JAPAN

CYA CELLULAR IMMUNOLOGY, (15 DEC 1999) VOL. 198, No. 2, PP. 111-119.
SO PUBLISHER: ACADEMIC PRESS INC, 525 B ST, STE 1900, SAN DIEGO, CA
92101-4495.
ISSN: 0008-8749.
DT Article: Journal
FS Life
LA English
REC Reference Count: 27
*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS.

L6 ANSWER 4 OF 211 SCISEARCH COPYRIGHT 2003 ISI (R)
AN 1999:385381 SCISEARCH
GA The Genuine Article (R) Number: 195KH
TI Blast cell-surface and plasma soluble urokinase receptor in acute leukemia
patients: Relationship to classification and response to therapy
AU Mustajoki S (Reprint); Alitalo R; Stephens K W; Vaheri A
UNIV HELSINKI, HAARTMAN INST, DEPT VIROL, POB 21, FIN-00014 HELSINKI.
FINLAND (Reprint); UNIV HELSINKI, HAARTMAN INST, TRANSPLANT LAB,
FIN-00014 HELSINKI, FINLAND; UNIV HELSINKI, CENT HOSP, DEPT MED, DIV
HAEMATOLOGY, HELSINKI, FINLAND; RIGSHOSP, FINSEN INST, DK-2100 COPENHAGEN,
DENMARK

CYA FINLAND: DENMARK
SO THROMBOSIS AND HAEMOSTASIS, (MAY 1999) VOL. 81, No. 5, PP. 705-710.
PUBLISHER: F K SCHATTNER VERLAG GMBH, P O BOX 10 45 45, LENZHALDE 3,
D-70040 STUTTGART, GERMANY.
ISSN: 0340-6245.
DT Article: Journal
FS Life
LA English
REC Reference Count: 37
*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS.

L6 ANSWER 5 OF 211 SCISEARCH COPYRIGHT 2003 ISI (R)
AN 1999:284019 SCISEARCH
GA The Genuine Article (R) Number: 183VG
TI Ischemia- and cytokine-induced mobilization of bone
marrow-derived endothelial progenitor cells for neovascularization
Takahashi T; Kaika C; Maeda H; Chen D; Silver M; Kearney M; Wagner M;
Isner J M (Reprint); Asanuma T
TUFTS UNIV, ST ELIZABETHS MED CTR, SCH MED, DEPT MED CARDIOL, 736
CAMBRIDGE ST, BOSTON, MA 02135 (Reprint); TUFTS UNIV, ST ELIZABETHS MED
CTR, SCH MED, DEPT MED CARDIOL, BOSTON, MA 02135; TUFTS UNIV, ST
ELIZABETHS MED CTR, SCH MED, DEPT BIOMED RES, BOSTON, MA 02135
USA

CYA NATURE MEDICINE, (APR 1999) Vol. 5, No. 4, PP. 434-438.
SO PUBLISHER: NATURE AMERICA INC, 345 PARK AVE SOUTH, NEW YORK, NY
10010-1707.
ISSN: 1078-8956.
DT Article: Journal
FS Life: CLIN
LA English
REC Reference Count: 18
*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS.

L6 ANSWER 6 OF 211 USPATFULL
AN 1999:170382 USPATFULL
TI Methods of screening for compounds that derepress or increase telomerase
activity
West, Michael D., San Carlos, CA, United States
Harley, Calvin B., Palo Alto, CA, United States
Weinrich, Scott L., San Francisco, CA, United States
Strahl, Catherine W., San Francisco, CA, United States

McEneaney, Michael J., San Francisco, CA, United States
 Shay, Jerry, Dallas, TX, United States
 Wright, Woodring E., Arlington, TX, United States
 Blackburn, Elizabeth H., San Francisco, CA, United States
 Kim, Nam Moo, Sunnyvale, CA, United States
 Vaziri, Homayoun, Toronto, Canada
 Board of Regents, The University of Texas System, Dallas, TX, United States (U.S. corporation)
 The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
 Genon Corporation, Menlo Park, CA, United States (U.S. corporation)
 PI US 6007989 19991228
 AI US 1997-81967 19970314 (8)
 RLI Division of Ser. No. US 153051
 DT Utility
 FS Granted
 LN.CNT 6145
 INCL INCLM: 435/006.000
 INCLS: 435/004.000; 435/007.200; 435/015.000; 435/091.200; 435/091.100; 435/375.000
 NCLM: 435/006.000
 NCLS: 435/004.000; 435/007.200; 435/015.000; 435/091.100; 435/091.200; 435/375.000
 IC [6]
 ICM: C120001-68
 ICS: C12P019-34
 435/6; 435/91.2; 435/15; 435/7.1; 435/4; 435/375; 435/91.1; 935/33;
 935/77; 935/78
 EXF 935/77; 935/78
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L6 ANSWER 7 OF 211 USPTFUL
 AN 1999.167046 USPTFUL
 TI IL-8 receptor antagonists
 IN Widdowson, Katherine Louisa, King of Prussia, PA, United States
 Weber, Daniel Frank, Ambler, PA, United States
 Herczberg, Anthony Joseph, Royersford, PA, United States
 Herczberg, Robert Philip, Downingtown, PA, United States
 Rutledge, Jr., Melvin Clarence, Lansdale, PA, United States
 Smithline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
 PI US 6005008 19991221
 WO 9625157 19960822
 US 1997-894291
 WO 1996-US2260
 AI 19970815 (8)
 19960216
 19970815
 19970815 PCT 371 date
 19970815 PCT 102(e) date
 DT Utility
 FS Granted
 LN.CNT 4760
 INCL INCLM: 514/596.000
 INCLS: 514/597.000; 514/598.000; 564/048.000; 564/049.000; 564/050.000; 564/052.000
 NCLM: 514/596.000
 NCLS: 514/597.000; 514/598.000; 564/048.000; 564/049.000; 564/050.000; 564/052.000
 IC [6]
 ICM: A61K031-17
 ICS: C07C273-00
 514/596; 514/597; 514/598; 564/48; 564/49; 564/50; 564/52
 EXF 514/596; 514/597; 514/598; 564/48; 564/49; 564/50; 564/52
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L6 ANSWER 8 OF 211 USPTFUL
 AN 1999.159475 USPTFUL
 TI Stimulation of host defense mechanisms against tumors
 IN Tovey, Michael Gerard, Paris, France

Kaido, Thomas James, San Diego, CA, United States⁴¹
 Pharma Pacific Pty Ltd., Brighton-Le-Sands, Australia (non-U.S. corporation)
 PI US 5997858 19991207
 AI US 1997-853293 19970509 (8)
 PRAI AU 1996-9765 19960509
 DT Utility
 FS Granted
 LN.CNT 987
 INCL INCLM: 424/085.400
 INCLS: 424/085.500; 424/085.600; 424/085.700; 424/001.110; 424/278.100; 514/002.000; 530/351.000
 NCLM: 424/085.400
 NCLS: 424/001.110; 424/085.500; 424/085.600; 424/085.700; 424/278.100; 514/002.000; 530/351.000
 IC [6]
 ICM: A61K038-21
 ICS: C07K014-555; C07K014-56; C07K014-57
 424/85.4; 424/85.5; 424/85.6; 424/85.7; 424/1.11; 424/278.1; 514/2;
 530/351
 EXF 424/85.4; 424/85.5; 424/85.6; 424/85.7; 424/1.11; 424/278.1; 514/2;
 530/351
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L6 ANSWER 9 OF 211 USPTFUL
 AN 1999.155675 USPTFUL
 TI Interferon-inducible protein 10 is a potent inhibitor of
 IN angiogenesis
 Tobac, Giovanna, Bethesda, MD, United States
 Angiolillo, Anne U., Washington, DC, United States
 Sgadari, Cecilia, Bethesda, MD, United States
 The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
 PI US 5994292 19991130
 US 1995-455079 19950531 (8)
 DT Utility
 FS Granted
 LN.CNT 1728
 INCL INCLM: 514/002.000
 INCLS: 514/004.000; 514/012.000; 514/021.000; 530/300.000; 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/328.000
 NCLM: 514/002.000
 NCLS: 514/004.000; 514/012.000; 514/021.000; 530/300.000; 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/328.000
 IC [6]
 ICM: A61K038-00
 514/12; 514/21; 514/214; 514/2; 514/4; 530/324; 530/300; 530/325;
 530/326; 530/327; 530/328; 424/85.7; 424/85.2; 424/85.1
 EXF 514/12; 514/21; 514/214; 514/2; 514/4; 530/324; 530/300; 530/325;
 530/326; 530/327; 530/328; 424/85.7; 424/85.2; 424/85.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L6 ANSWER 10 OF 211 USPTFUL
 AN 1999.141975 USPTFUL
 TI Therapeutic inhibitor of vascular smooth muscle cells
 IN Kunz, Lawrence U., Redmond, WA, United States
 Klein, Richard A., Edmonds, WA, United States
 Reno, John M., Brier, WA, United States
 Neorx Corporation, Seattle, WA, United States (U.S. corporation)
 PI US 5981568 19991109
 US 1997-829685 19970331 (8)
 Continuation-in-part of Ser. No. US 1995-450793, filed on 25 May 1995, now patented, Pat. No. US 5811447 which is a continuation of Ser. No. US 1993-62451, filed on 13 May 1993, now abandoned And a continuation-in-part of Ser. No. WO 1996-US2125, filed on 15 Feb 1996 which is a continuation-in-part of Ser. No. US 1995-389712, filed on 15 Feb 1995
 DT Utility
 FS Granted

LN.CNT 5553
INCL INCLM: 514/411.000
INCL: 514/459.000; 514/319.000; 514/324.000; 514/422.000; 514/428.000
NCL NCLM: 514/411.000
NCL: 514/319.000; 514/324.000; 514/422.000; 514/428.000; 514/499.000
IC [6]
ICM: A61K031-40
EXP 514/499; 514/411; 514/319; 514/324; 514/422; 514/428
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 11 OF 211 USPTAFULL
AN 1999:11637 USPTAFULL
TI Polynucleotide encoding chemokine, beta-4
IN Li. Haedong, Gathersburg, MD, United States
PA Adams, Mark D., North Potomac, MD, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. CORPORATION)
PI US 5981230 19991109
AI US 1995-458355 19950602 (8)
RLI Continuation-in-part of Ser. No. WO 1994-US9484, filed on 23 Aug 1994
DT Utility
FS Granted
LN.CNT 1648
INCL INCLM: 435/069.500
INCL: 536/023.100; 536/023.500; 536/024.300; 536/024.310; 435/471.000;
435/325.000; 435/252.300; 435/320.100; 435/071.200; 530/324.000
NCL NCLM: 435/069.500
NCL: 435/071.200; 435/252.300; 435/320.100; 435/325.000; 435/471.000;
530/324.000; 536/023.100; 536/023.500; 536/024.300; 536/024.310
IC [6]
ICM: C12N015-19
EXP 536/23.1; 536/23.5; 536/24.3; 536/24.31; 435/69.5; 435/172.3; 435/240.2;
435/240.3; 435/252.3; 435/320.1; 435/70.1; 435/71.1; 435/71.2; 435/325;
435/471; 935/11; 935/22; 935/52; 935/66; 530/324
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 12 OF 211 USPTAFULL
AN 1999:11294 USPTAFULL
TI Methods for enhancing angiogenesis with endothelial progenitor
IN cells
IN Isner, Jeffrey M., Weston, MA, United States
PA Asahara, Takayuki, Arlington, MA, United States
PA St. Elizabeth's Medical Center of Boston, Boston, MA, United States
PI US 5980887 19991109
AI US 1996-744882 19961108 (8)
DT Utility
FS Granted
LN.CNT 1104
INCL INCLM: 424/093.700
INCL: 424/085.100; 424/085.200; 514/008.000; 514/044.000
NCL NCLM: 424/093.700
NCL: 424/085.100; 424/085.200; 514/008.000; 514/044.000
IC [6]
ICM: A61K035-12
EXP 424/93.7; 424/85.4; 424/85.2; 435/325; 435/375; 514/2; 514/6; 514/44;
530/351; 053/22.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 13 OF 211 USPTAFULL
AN 1999:117298 USPTAFULL
TI Secreted proteins and polynucleotides encoding them
IN Jacobs, Kenneth, Newton, MA, United States

McCoy, John M., Reading, MA, United States
Racie, Lisa A., Acton, MA, United States
Lavallee, Edward R., Tewksbury, MA, United States
Merberg, David, Acton, MA, United States
Treacy, Maurice, Chestnut Hill, MA, United States
Evans, Cheryl, Woburn, MA, United States
Genetics Institute, Inc., Cambridge, MA, United States (U.S. CORPORATION)
PI US 5958726 19990928
AI US 1997-667680 19970602 (8)
RLI Continuation-in-part of Ser. No. US 1996-63511, filed on 19 Apr 1996
DT Utility
FS Granted
LN.CNT 1766
INCL INCLM: 435/069.100
INCL: 435/091.100; 435/091.200; 435/091.500; 435/252.300; 435/320.100;
536/023.100; 536/023.500; 536/024.310; 530/350.000
NCL NCLM: 435/069.100
NCL: 435/091.100; 435/091.200; 435/091.500; 435/252.300; 435/320.100;
530/350.000; 536/023.100; 536/023.500; 536/024.310
IC [6]
ICM: C12N015-00
EXP 435/69.1; 435/252.3; 435/320.1; 435/91.1; 435/91.2; 435/91.5; 536/23.1;
536/23.5; 536/24.31; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 14 OF 211 USPTAFULL
AN 1999:113778 USPTAFULL
TI Carboxylic acid indole inhibitors of chemokines
IN Thompson, Scott K., Phoenixville, PA, United States
Halbert, Stacie M., Harleyville, PA, United States
Waldow, Katherine L., King of Prussia, PA, United States
SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. CORPORATION)
PI US 5955492 19990921
AI WO 9735572 19971002
US 1998-155220
WO 1997-US4938
PCT 371 date
PCT 102(e) date

PRAI US 1996-14257P 19960328 (60)
DT Utility
FS Granted
LN.CNT 1093
INCL INCLM: 514/419.000
INCL: 514/382.000; 514/784.000; 514/826.000; 514/863.000; 548/250.000;
548/252.000; 548/254.000; 548/490.000; 548/491.000; 548/494.000;
549/440.000; 562/405.000; 562/466.000; 562/468.000
NCL NCLM: 514/419.000
NCL: 514/382.000; 514/784.000; 514/826.000; 514/863.000; 548/250.000;
548/252.000; 548/254.000; 548/490.000; 548/491.000; 548/494.000;
549/440.000; 562/405.000; 562/466.000; 562/468.000
IC [6]
ICM: A61K031-405
EXP 514/419; 514/784; 548/490; 548/491; 548/494
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 15 OF 211 USPTAFULL
AN 1999:110187 USPTAFULL
TI DNA encoding the chemotactic cytokine III
IN Ni, Jian, Rockville, MD, United States
Gentz, Reiner, Silver Spring, MD, United States
Yu, Guo-Liang, Danestown, MD, United States
Su, Jeffrey, Gathersburg, MD, United States

PA Dillon, Patrick J., Gaithersburg, MD, United States
 Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
 PI US 5952197 19990914
 AI US 1997-812003 19970305 (8)
 PRAI US 1996-13609P 19960305 (60)
 DT Utility
 FS Granted
 LN.CNT 2323
 INCL INCLM: 435/069.500
 INCLS: 435/069.100; 435/352.300; 435/320.100; 536/023.500; 536/024.300
 NCLM: 435/069.500
 NCLS: 435/069.100; 435/252.300; 435/320.100; 536/023.500; 536/024.300
 IC [6]
 ICM: C12N015-19
 ICS: C12N015-00; C12N015-63
 EXF 536/23.5; 435/69.1; 435/69.5; 435/252.3; 435/320.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 16 OF 211 USPTFUL
 AN 1999:102965 USPTFUL
 TI Mouse model of psoriasis
 IN Parker, Christina M., Newton Centre, MA, United States
 Schon, Michael P., Boston, MA, United States
 Brigham & Women's Hospital, Inc., Boston, MA, United States (U.S. corporation)
 PA US 5945576 19990831
 PI US 1996-628761 19960405 (8)
 AI Utility
 FS Granted
 LN.CNT 1935
 INCL INCLM: 800/009.000
 INCLS: 435/375.000; 435/377.000; 424/093.700; 424/009.210
 NCLM: 800/009.000
 NCLS: 424/009.200; 424/093.700; 435/375.000; 435/377.000
 IC [6]
 ICM: C12N005-00
 ICS: C12N015-00; A01N063-00; A61K049-00
 EXF 435/375; 435/377; 800/2; 800/DIG.5; 800/DIG.4; 800/9; 424/93.7; 424/9.21
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 17 OF 211 USPTFUL
 AN 1999:89279 USPTFUL
 TI Macrophage derived chemokine and chemokine analogs
 IN Godiska, Ronald, Bethesda, MA, United States
 Gray, Patrick W., Seattle, WA, United States
 ICOS Corporation, Bothell, WA, United States (U.S. corporation)
 PA US 5932703 19990803
 PI US 1996-660542 19960607 (8)
 AI Continuation-in-part of Ser. No. US 1995-558658, filed on 16 Nov 1995
 RLI which is a continuation-in-part of Ser. No. US 1995-479620, filed on 7 Jun 1995
 DT Utility
 FS Granted
 LN.CNT 2745
 INCL INCLM: 530/351.000
 INCLS: 530/324.000; 930/140.000; 424/085.100
 NCLM: 530/351.000
 NCLS: 424/085.100; 530/324.000; 930/140.000
 IC [6]
 ICM: C07K014-52
 ICS: A61K038-19
 EXF 530/351; 530/324; 930/140; 424/85.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 18 OF 211 USPTFUL
 AN 1999:85601 USPTFUL
 TI IL-8 receptor antagonists
 IN Widdowson, Katherine L., King Prussia, PA, United States
 Nie, Hong, Conshohocken, PA, United States
 Rutledge, Jr., Melvin Clarence, Thousand Oaks, CA, United States
 SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)
 PA US 5929250 19990727
 PI US 1998-121264 19980723 (9)
 AI Continuation-in-part of Ser. No. WO 1998-US1292, filed on 23 Jan 1998
 PRAI US 1997-42830P 19970408 (60)
 DT Utility
 FS Granted
 LN.CNT 1462
 INCL INCLM: 548/361.100
 INCLS: 514/403.000
 NCLM: 548/361.100
 NCL [6]
 IC ICM: A61K031-415
 ICS: C07D231-56
 EXF 548/361.1; 514/403
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 19 OF 211 USPTFUL
 AN 1999:85471 USPTFUL
 TI Guadinidno, formamidino, amino and related compounds for inhibiting osteoclast-mediated bone resorption
 IN Hartman, George D., Lansdale, PA, United States
 Dugan, Mark E., Schwenksville, PA, United States
 Hoffman, William F., Lansdale, PA, United States
 Ihle, Nathan C., Mercer Island, WA, United States
 Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
 PA US 5929120 19990727
 PI US 1998-15982 19980130 (9)
 AI Division of Ser. No. US 1996-714097, filed on 26 Sep 1996, now patented.
 RLI Pat. No. US 5741796 which is a continuation-in-part of Ser. No. US 1994-250218, filed on 27 May 1994, now abandoned
 DT Utility
 FS Granted
 LN.CNT 3417
 INCL INCLM: 514/634.000
 INCLS: 514/567.000; 514/568.000; 514/619.000; 562/430.000; 562/439.000; 564/084.000; 564/170.000; 564/246.000; 564/247.000
 NCLM: 514/634.000
 NCLS: 514/567.000; 514/568.000; 514/619.000; 562/430.000; 562/439.000; 564/084.000; 564/170.000; 564/246.000; 564/247.000
 IC [6]
 ICM: A61K031-155
 ICS: A61K031-19; C07C257-10; C07C307-02
 EXF 514/256; 514/300; 514/311; 514/567; 514/568; 514/619; 514/634; 544/332; 544/333; 546/164; 546/177; 546/268.1; 546/290; 546/304; 562/430; 562/439; 564/84; 564/170; 564/246; 564/247
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 20 OF 211 USPTFUL
 AN 1999:65188 USPTFUL
 TI Polynucleotides encoding chemokine .alpha.-2
 IN Ni, Jian, Rockville, MD, United States
 Gentz, Reiner L., Silver Spring, MD, United States
 Su, Jeffrey Y., Gaithersburg, MD, United States
 Li, Haodong, Gaithersburg, MD, United States
 Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
 PA

PI US 5910431 19990608
AI US 1997-825556 19970319 (8)
DT Utility
FS Granted
LN.CNT 2491

INCL INCLM: 435/069.500 435/320.100: 536/023.500: 536/024.300: 536/024.330
INCLM: 435/252.300: 435/069.500
NCLM: 435/069.500
NCLM: 435/252.300: 435/320.100: 536/023.500: 536/024.300: 536/024.330
IC ICL: C12N001-00
ICS: C12N015-00
EXP 536/23.5: 536/24.3-24.33: 435/69.5: 435/752.3: 435/320.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

--Logging off of STN--

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	73.54	73.75
STN INTERNATIONAL LOGOFF AT 15:20:50 ON 31 MAR 2003		

WEST

End of Result Set



Generate Collection

Print

102^e Art?

L1: Entry 1 of 1

File: USPT

Nov 9, 1999

US-PAT-NO: 5980887

DOCUMENT-IDENTIFIER: US 5980887 A

TITLE: Methods for enhancing angiogenesis with endothelial progenitor cells

DATE-ISSUED: November 9, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Isner; Jeffrey M.	Weston	MA		
Asahara; Takayuki	Arlington	MA		

US-CL-CURRENT: 424/93.7; 424/85.1, 424/85.2, 514/44, 514/8

CLAIMS:

What is claimed is:

1. A method for inducing the formation of new blood vessels in an ischemic tissue in a patient in need thereof, comprising:

administering to said patient host an effective amount of an isolated endothelial progenitor cell to induce new blood vessel formation in said ischemic tissue, wherein said endothelial progenitor cell are CD34.sup.+, flk-1.sup.+ or tie-2.sup.+.

2. The method of claim 1, further comprising the step of administering to the patient an endothelial cell mitogen or a nucleic acid encoding an endothelial cell mitogen.

3. The method of claim 2, wherein the endothelial cell mitogen is selected from the group consisting of acidic and basic fibroblast growth factors, vascular endothelial growth factor, epidermal growth factor, transforming growth factor α and β , platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor α , hepatocyte growth factor, insulin like growth factor, erythropoietin, colony stimulating factor, macrophage-CSF, granulocyte/macrophage CSF and nitric oxidesynthase.

4. The method of claim 3, wherein the endothelial cell mitogen is vascular endothelial growth factor.

5. The method of claim 1, wherein said patient is in need of treatment for cerebrovascular ischemia, renal ischemia, pulmonary ischemia, limb ischemia, ischemic cardiomyopathy and myocardial ischemia.

6. A method of enhancing blood vessel formation in a patient in need thereof, comprising:

a. selecting the patient in need thereof;

b. isolating endothelial progenitor cells from the patient, wherein said endothelial progenitor cell are CD34.sup.+, flk-1.sup.+ or tie-2.sup.+ ; and

c. readministering the endothelial progenitor cells to the patient.

7. A method for treating an injured blood vessel in a patient in need thereof, comprising:

a. selecting the patient in need thereof; and

b. isolating endothelial progenitor cells from the patient, wherein said endothelial progenitor cell are CD34.sup.+, flk-1.sup.+ or tie-2.sup.+ ; and

c. readministering the endothelial progenitor cells to the patient.

8. The method of claim 7, wherein the injury is the result of balloon angioplasty.

9. The method of claim 7, wherein the injury is the result of deployment of an endovascular stent.

10. The method of claim 7, further comprising the step of administering to the patient an endothelial cell mitogen or a nucleic acid encoding an endothelial cell mitogen.

11. The method of claim 10, wherein the endothelial cell mitogen is selected from the group consisting of acidic and basic fibroblast growth factors, vascular endothelial growth factor, epidermal growth factor, transforming growth factor a and .beta., platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor .alpha., hepatocyte growth factor, insulin like growth factor, erythropoietin, colony stimulating factor, macrophage-CSF, granulocyte/macrophage CSF and nitric oxidesynthase.